Citi Keeps Their Buy Rating on Temple & Webster Group Ltd (TPLWF)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Teeger covers the Consumer Cyclical sector, focusing on stocks such as ARB Corporation , Breville Group , and Collins Foods . According to TipRanks, Teeger has an average return of 3.5% and a 44.93% success rate on recommended stocks.
Currently, the analyst consensus on Temple & Webster Group Ltd is a Strong Buy with an average price target of $12.55, implying a 31.27% upside from current levels. In a report released on May 8, Petra Capital also maintained a Buy rating on the stock with a A$20.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
32 minutes ago
- Business Insider
Why Walmart (WMT) is Poised to Validate Its Premium Valuation
The Minneapolis-based retailer Walmart's (WMT) fiscal Q2 earnings are just around the corner, with results expected to be published before market open on Thursday, August 21st. The company is steadily climbing back toward its all-time high of $105 per share, last seen in February, as tariff risks are absorbed and U.S. consumer demand proves strong and resilient. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Momentum remains clearly bullish, with analysts nudging their top- and bottom-line estimates slightly higher over the past month. All signs point to another solid—though not exactly thrilling—quarter for top-line growth. I'm still not a huge fan of Walmart's valuation, especially with free cash flow yields just a bit over 1%, where I think it could be far more compelling. That said, I can't ignore Walmart's impressive cash flow generation. So, I'm still leaning toward a Buy rating, supported by solid economic tailwinds and pricing resilience, with the stock likely to make another run toward those all-time highs. Tariff Absorption and Walmart's Advantage Over the past few months, the rise in U.S. import tariffs has been a key theme supporting Walmart's thesis, given how sensitive the company is to pricing. The relevant concept here is 'tariff absorption,' where exporters choose to absorb some of the tariff costs so they don't lose share in the valuable U.S. market. For Walmart, as a price leader and inflation fighter with around 200 million customers, the chain manages to keep prices low even in inflationary scenarios. Its extensive physical footprint and high customer traffic let it combine scale and convenience, allowing the company to absorb costs much better than smaller competitors. Walmart also has a history of pressuring suppliers to keep prices down. For suppliers, it often makes sense to absorb part of the extra tariff costs to continue selling to Walmart—losing Walmart as a customer would mean giving up huge volumes. That said, CEO Doug McMillon has noted that tariff increases are likely to push prices higher for consumers eventually, and these changes are expected to roll out throughout the second half of 2025. Even so, my take is that Walmart will likely continue benefiting from high import tariffs, with suppliers bearing most of the cost—especially as customers keep buying and reinforcing the company's value proposition. Strong Consumer Demand Should Drive Walmart Forward In addition to tariffs likely being absorbed, another factor supports the idea that Walmart should post amiable numbers for Q2. June and Q2 2025 retail data show that consumer demand remains solid, with retail and food services up 3.9% year-over-year and Q2 sales up 4.1%. Growth is robust in essentials like groceries and food services, while digital retail continues to expand, up 4.5% YoY. This combination of healthy spending creates a bullish backdrop for Walmart's Q2, which should translate into solid same-store sales, steady traffic, and overall earnings momentum. On top of that, the 'One Big Beautiful Bill Act' of 2025 temporarily doubled the income tax credit for families with children, raising the maximum to $2,500 per child through 2028. The goal is to stimulate consumption, especially among low- and middle-income families. Naturally, this injection of funds tends to benefit retailers like Walmart, which serve this audience and sell essential products. Given these factors, it wouldn't be surprising to see U.S. comp sales growth in Q2 match or even exceed the 4.5% posted in Q1. Additionally, Walmart's net income margin is currently 2.75%, slightly below past levels above 3%, suggesting room for expansion. The company has grown EBIT margins for six consecutive quarters, and the trend is likely to continue in Q2, especially with management expressing confidence in navigating tariff pressures and growing profits faster than sales. Valuations are one of the most sensitive parts of the broader market thesis, with Walmart currently trading at 44x earnings. The market is essentially projecting that the company will double its profits over the next six years if the business continues at its current pace. While this multiple seems high compared to the industry average of 17.5x, a key attraction of the thesis is Walmart's stable cash generation—with free cash flow close to $10 billion over the last twelve months—and sustainable growth, offering both capital protection and upside. Even with a free cash flow yield of just 1.2%, it's reasonable to accept a lower yield in exchange for low volatility and predictability. For context, looking at the options market, the at-the-money straddles closest to expiration after Q2 earnings suggest an expected earnings move of ~4.71%, which is relatively low, especially compared to technology companies that often see double-digit earnings moves. For Walmart, earnings moves typically range between 3% and 6%, depending on the quarter, so current expectations are well within the historical range. Is Walmart a Buy, Hold, or Sell? Analysts have been overwhelmingly bullish on Walmart. All 27 analysts covering the stock via TipRanks are expecting higher prices in the next twelve months. Moreover, WMT's average price target of $113 implies an upside potential of 12%. Tailwinds Keep Walmart's Bull Case Intact The setup appears favorable for Walmart heading into its second-quarter results. Consumer spending tailwinds supported by recent retail data, limited tariff-related impacts, and margin expansion driven by strong same-store sales suggest a positive outlook. While the stock's premium valuation already reflects much of this strength, paying up for a business with a relatively low risk of underperformance remains compelling in the current environment. Accordingly, I maintain a Buy rating on WMT ahead of earnings.
Business Insider
an hour ago
- Business Insider
Nintendo Stock (NTDOF) Slips Despite Double Switch 2 Screens Patent
Nintendo (NTDOF) stock was on the move Friday alongside an updated patent from the video game company. This new patent highlights a potential additional screen that could be added to one of its gaming devices, likely the Switch 2. The second screen in the patent would attach to the top of the console, allowing it to display two screens at once. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. A possible use case for this would be playing Nintendo DS or 3DS games on the Switch 2. Nintendo already has emulation of other game consoles available on the Switch 2 through its Nintendo Online subscription service, such as Nintendo, Super Nintendo, Game Boy, Game Boy Advance, and most recently, GameCube. While the idea of purchasing a second screen to play DS games on the Switch 2 may seem odd to some, it's not too different from current practices. Nintendo sells updated versions of classic Nintendo controllers to its Online subscribers. The second screen could be sold through this same service. Nintendo could also allow DS emulation on the Switch via a vertical display orientation for those who want to play the games but not purchase the second screen. Nintendo Stock Movement Today Nintendo stock was down 0.77% on Friday, following a rally in earlier trading. Despite the dip, NTDOF stock has increased 65.55% year-to-date and 78.95% over the past 12 months. The success of the Switch 2 has been a major positive catalyst for the company's shares. Is Nintendo Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Nintendo is Moderate Buy, based on nine Buy, two Hold, and a single Sell rating over the past three months. With that comes an average NTDOF stock price target of $98.61, representing a potential 2.29% upside for the shares.
Yahoo
an hour ago
- Yahoo
Insiders Snap Up These 2 Stocks on the Dip — Here's Why They Draw Plaudits from Goldman Sachs
Every investor looks for signs that a stock might be worth the leap. While no single indicator guarantees success, some signals stand out as especially powerful when they appear together. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One of the most reliable is insider buying. These are high-level executives and directors who have an intimate understanding of their company's operations, prospects, and challenges. They tend to put their own money on the line only when they believe the stock's future value will be higher. Better yet, their trades must be disclosed publicly, giving everyday investors a chance to watch and follow their moves. Another time-tested signal is the 'buy low, sell high' principle, spotting beaten-down stocks that have been oversold and may be poised for recovery. Price declines can sometimes signal trouble, but they can also reflect market overreactions, offering attractive entry points for those willing to look past the noise. The picture gets even stronger when this combination is validated by a heavyweight endorsement from Wall Street. A Buy rating from a firm like Goldman Sachs is more than an opinion – it's typically backed by deep research, robust industry modeling, and high-conviction guidance to clients. Such endorsements can boost investor confidence and help catalyze momentum. Against this backdrop, we've used the TipRanks database to pinpoint two stocks where all three forces align: insiders are buying, valuations look attractive after recent pullbacks, and Goldman Sachs is flashing a green light. When these signals converge, it's a setup that few investors can afford to ignore. Shift4 Payments (FOUR) We'll start our look at insider buying with Shift4 Payments, a payment processing company based in Pennsylvania that traces its roots back to 1999, when a teenage Jared Isaacman launched it from his parents' basement. His mission was to fill an 'efficiency niche' in payment processing by reducing the time and cost for merchants to get up and running. Today, the company sports a market cap approaching $8 billion and generates more than $3 billion in annual revenue. Over the years, Shift4 has expanded well beyond its early merchant focus. Its payment processing solutions now cater to customers across a wide range of industries, marketed as simple, safe, scalable, and smart – and tailored to individual client needs. Complementing these services, Shift4 offers point-of-sale systems, contactless commerce, and mobile payment capabilities. With offices across North America and Europe, the company supports over 100 payment methods in more than 150 currencies worldwide. That global reach got another boost on July 3, when Shift4 completed its $2.5 billion acquisition of Global Blue, a specialty payments and tech platform focused on international transactions, including tax-free shopping and currency conversion. The deal, priced at $7.50 per share, further strengthens Shift4's ability to serve cross-border clients. Such moves have helped the company build an impressive footprint: more than 200,000 customers, 500-plus technology integrations, and over 5 billion annual transactions totaling more than $260 billion. Yet, despite this strong operational base, the stock is down 14% year-to-date. The most recent spate of losses came after the August 5 earnings release for 2Q25. In that release, Shift4 showed quarterly revenues of $966.2 million, a figure that was up nearly 17% year over year but missed the forecast by just over $12 million. At the bottom line, the company's non-GAAP EPS of $1.10 also missed the forecast, coming in 10 cents per share lower than had been expected. Following the post-earnings pullback, founder and chairman Jared Isaacman moved quickly to buy the dip, scooping up 196,426 Shift4 shares between August 8 and August 11 for nearly $16.27 million, a move that signals strong confidence in the company's long-term prospects. That conviction appears to be shared on Wall Street, with Goldman Sachs analyst Will Nance viewing Shift4 as a potential growth story. 'We view FOUR as one of the top growth stories in our coverage and are constructive on the company's unique approach to M&A that has resulted in FOUR maintaining high levels of growth without incurring outsized customer acquisition costs. We expect this M&A strategy to continue, both in existing markets and increasingly in international markets. On that note, we believe that the Global Blue deal represents a solid addition to the company's customer acquisition funnel in Europe, and expect that FOUR has the potential to exceed its top line revenue synergy targets as it targets the low end of the Global Blue customer base, a group that historically relies on bank and legacy payment processors,' Nance opined. 'Importantly,' the analyst added, 'we believe FOUR can achieve these targets without any major enterprise wins, which we think is a common point of misunderstanding in the market, as some investors perceived the deal as FOUR looking to compete head to head with modern enterprise processors such as Adyen.' Quantifying this stance, Nance rates FOUR shares as a Buy, with a $104 price target that implies a ~17% upside for the coming year. (To watch Nance's track record, click here) Overall, Shift4's stock holds a Strong Buy consensus rating, based on 22 analyst reviews that include 17 Buys against 5 Holds. The shares are priced at $89.11, and their $107.75 average price target indicates room for a ~21% gain on the one-year horizon. (See FOUR stock forecast) Vertex Pharmaceuticals (VRTX) The next stock that has the combination of strong insider buys, a share price on the dip, and a bullish nod from Goldman Sachs is Vertex Pharmaceuticals. This company is a biotech researcher, with both a pipeline of drug candidates under development and a portfolio of approved medications on the market. That combination is something of a 'Holy Grail' for biotechs – and Vertex has reaped the rewards. The company was founded in 1989 and has since built itself into a $100 billion player in the field. Vertex's portfolio currently includes seven approved medications, and the company generated revenues of $11 billion last year and nearly $10 billion in 2023, with the bulk of that revenue coming from product sales. Vertex's product portfolio includes Trikafta, its largest revenue generator, which is a treatment for cystic fibrosis, and Kalydeco, another cystic fibrosis treatment, which was approved in 2012 and is Vertex's first approved drug. The company's most recently approved drugs are Casgevy, a treatment for sickle cell disease, approved in 2023; Alyftrek, a CF treatment for patients over age 6, approved in 2024; and Journavx, a non-opioid pain treatment approved in January of this year. The company's commercialized medications provided the bulk of its $2.96 billion in total quarterly revenue in 2Q25, the last period reported; of that total, $2.55 billion came from sales of Trikafta. Vertex's strong revenue totals support its research pipeline, under which the company continues to develop treatments for a wide range of conditions, including kidney disease, severe pain, beta thalassemia, and diabetes, as well as additional treatments for cystic fibrosis and sickle cell disease. The latest news about the company came from that development program, specifically as it relates to VX-993, a treatment for acute pain that was the subject of a recently completed Phase 2 clinical trial. On August 4, the same day that the company released its 2Q25 results, Vertex also announced that VX-993 failed to meet the primary endpoints of the study and will not be developed further as an acute pain monotherapy. The stock price has dropped sharply since that day and has not recovered; it is still down by 17%. That drop has not gone unnoticed in the C-suite. On August 6, two top insiders made substantial purchases: President and CEO Reshma Kewalramani bought 10,000 shares for nearly $3.9 million, and board member Bruce Sachs acquired 5,000 shares for $1.95 million. Goldman Sachs analyst Salween Richter shares that conviction, pointing to the company's expanding lineup of commercial products and the strength of several clinical-stage candidates. 'We recommend owning VRTX on continued commercial execution as demonstrated by the recent launches of Alyftrek in cystic fibrosis, noting a majority of treated patients are switch patients, and Journavx in acute pain, ahead of a 2H inflection, where we acknowledge access/reimbursement progress (inclusive of two of the three largest PBMs – the last is expected by YE); and potential emergence of a third commercial lever in povetacicept, where an interim analysis of the Ph3 RAINIER trial in IgA nephropathy (IgAN) could support an accelerated approval filing in 1H26, with expansion into other autoimmune renal diseases and cytopenias,' Richter wrote. Richter goes on to rate VRTX stock as a Buy and sets a $624 price target that indicates room for an upside of ~60% by this time next year. (To watch Richter's track record, click here) Overall, shares in Vertex hold a Moderate Buy consensus rating, based on 27 recent analyst reviews that split to 16 Buys and 11 Holds. The stock is priced at $390.30, and its average price target, now at $491.78, suggests a one-year upside potential of 26%. (See VRTX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
